BioCentury
ARTICLE | Company News

Baylor, Cell Medica deal

July 25, 2016 7:00 AM UTC

Baylor granted Cell Medica exclusive rights to co-develop and commercialize Baylor’s cell and gene technologies to treat solid tumors. The deal includes a license and options for two platform patents related to engineered natural killer T (NKT) cells, three target cancer antigens for chimeric antigen receptor (CAR)-modified NKT cells and a genetically engineered T cell receptor (TCR) for use in NKT and T cells. ...